Beijing Balance Medical Technology Co.,Ltd. (SHA:688198)
China flag China · Delayed Price · Currency is CNY
102.59
+1.84 (1.83%)
At close: Mar 6, 2026

SHA:688198 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
146.33115.2195.1351.2
Depreciation & Amortization
22.7213.76.836.93
Other Amortization
2.670.530.530.46
Loss (Gain) From Sale of Assets
-0-0.06-0.01-0.01
Asset Writedown & Restructuring Costs
0.0500.020.03
Loss (Gain) From Sale of Investments
-10.75-17.87-22.3-15.9
Provision & Write-off of Bad Debts
2.391.461.10.81
Other Operating Activities
-13.68-5.36-0.030.17
Change in Accounts Receivable
-63.04-30.18-22.36-30.26
Change in Inventory
-17.84-3.42-9.52-5.61
Change in Accounts Payable
39.2930.8214.3415.96
Change in Other Net Operating Assets
18.1229.258.2480.95
Operating Cash Flow
136.23141.17128.8576.49
Operating Cash Flow Growth
-3.50%9.56%68.44%50.69%
Capital Expenditures
-163.26-128.63-104.83-72.22
Sale of Property, Plant & Equipment
0.020.310.090.02
Cash Acquisitions
-10.84-43.28--
Investment in Securities
-235.4237.72-29.16-8.56
Other Investing Activities
133.2413.1818.8816.13
Investing Cash Flow
-276.2379.3-115.02-64.64
Long-Term Debt Repaid
-4.25-2.61-1.39-
Net Debt Issued (Repaid)
-4.25-2.61-1.39-
Issuance of Common Stock
14.4816.911.3410.78
Common Dividends Paid
-109.26-67.84-48.22-19.2
Other Financing Activities
-0-0-0.04-0.87
Financing Cash Flow
-99.03-53.54-38.31-9.29
Foreign Exchange Rate Adjustments
0.01-00-
Net Cash Flow
-239.03166.92-24.492.57
Free Cash Flow
-27.0212.5324.014.27
Free Cash Flow Growth
--47.80%462.20%-90.08%
Free Cash Flow Margin
-5.38%3.38%8.14%1.70%
Free Cash Flow Per Share
-0.200.090.180.03
Cash Interest Paid
--0-
Cash Income Tax Paid
23.0614.954.5921.09
Levered Free Cash Flow
-83.75-43.522.12-2.35
Unlevered Free Cash Flow
-83.47-43.262.17-2.28
Change in Working Capital
-13.4933.5647.5932.8
Source: S&P Global Market Intelligence. Standard template. Financial Sources.